drugset
drugset / Trial / NCT04124991

Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC

NCT04124991 ↗

Phase 1/2 Completed 24 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

Safety and Efficacy Study of Radioembolization with Yttrium-90 Microspheres in Combination with Durvalumab in Locally Advanced Hepatocellular Carcinoma

Timeline

Start
2020-06-12
Primary completion
2022-07-06
Completion
2022-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 1500 mg Intravenous

Indications

hepatocellular carcinoma